Your browser doesn't support javascript.
loading
Effects of Roflumilast on Lung Function of Asian Patients with Chronic Obstructive Pulmonary Disease :a Meta-analysis / 中国药房
China Pharmacy ; (12): 1112-1117, 2019.
Artigo em Chinês | WPRIM | ID: wpr-816999
ABSTRACT
OBJECTIVE: To systematically evaluate the effects of roflumilast on lung function of Asian patients with chronic obstructive pulmonary diseaseCOPD), and to provide evidence-based reference for rational drug use in the clinic. METHODS: Retrieved from Cochrane libraryPubMed, Embase, CBM, CNKI, VIP and Wanfang database, RCTs about roflumilast or roflumilast combined with routine treatment or placebo (trial group) versus routine treatment or placebo (control group) in the treatment of Asian COPD patients were collected. After literature screening, data extraction and quality evaluation with Cochrane bias risk evaluation tool, Meta-analysis was conducted by using Rev Man 5.2 software. RESULTS: Totally 6 RCTs were included, involving 1 494 patients. Meta-analysis showed that pre-bronchodilator FEV1 (pre-FEV1) [MD=75.19, 95%CI(53.21, 97.17), P<0.000 01], post-bronchodilator FEV1 (post-FEV1) [MD=56.60, 95%CI(27.56, 85.63), P=0.000 1], forced vital capacity (FVC) [MD=43.67, 95%CI (15.91,71.43), P=0.002], average flow rate of post-bronchodilator 25%-75% of forced vital capacity (post-FEF25%-75%) [MD=14.58, 95%CI (8.43, 20.73), P<0.001], the incidence of diarrhea [RR=5.06, 95%CI (1.26,20.27), P=0.02], respiratory infection [RR=1.94, 95%CI (1.30,2.90), P=0.001], decreased appetite [RR=7.43, 95%CI (2.94,18.79), P=0.001], body weight decrease [RR=5.46, 95%CI (2.12,14.03), P=0.001], headache [RR=7.73, 95%CI (1.42,42.16), P=0.02], dizziness [RR=3.44, 95%CI (1.28,9.27), P=0.01], gastritis [RR=5.09, 95%CI (1.49, 17.45), P=0.01] and anorexia [RR=5.06, 95%CI (1.97, 13.00), P=0.001] in trial group were significantly higher than control group; St. George’s Respiratory Questionnaire (SGRQ) total score [MD=-5.82, 95%CI(-7.77, -3.87), P<0.001], respiratory symptom score [MD=-1.67, 95%CI (-2.51,  -0.84), P<0.001], activity limited score [MD=-1.55,   95%CI (-2.14, -0.97), P<0.001] and disease impact score [MD=-2.59, 95%CI (-3.40,-1.79), P<0.001] of trial group were significantly lower than those of control group. CONCLUSIONS: Roflumilast can improve lung function and dyspnea in Asian COPD patients, but it can increase the risk of ADR.

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Tipo de estudo: Ensaio Clínico Controlado / Revisões Sistemáticas Avaliadas Idioma: Chinês Revista: China Pharmacy Ano de publicação: 2019 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Tipo de estudo: Ensaio Clínico Controlado / Revisões Sistemáticas Avaliadas Idioma: Chinês Revista: China Pharmacy Ano de publicação: 2019 Tipo de documento: Artigo